Nimitt Consulting Inc.

Last chance to register for next week's SCT and CAR-T webinar! Join us on Oct 22nd from 2-4 EDT for real-time problem-solving of complex questions administrators and other stakeholders face. Registration information available here: [https://lnkd.in/gSshpGtr]. #webinar #SCT #CAR-T

Did you know that most payers are legally required to cover routine costs related to clinical trial treatment?   Read our latest for guidance on how to plan, communicate and advocate for patient access and fair reimbursement!

Exciting Update to the Speaker Line-Up!    Nimitt has expanded the expert speakers for our first-ever educational webinar for Cell Therapy Program Administrators. We are delighted that Kristen Muncy will join us to discuss optimizing Managed Care aspects of CAR-T and SCT reimbursement. Please see below link for registration and more information.   https://lnkd.in/gSshpGtr

Stakeholders need to submit comments to CMS asking the agency to recognize separate payment for CAR-T cell collection and cell processing services in both the hospital setting and in free-standing physician offices when services are provided there. Comments are due Sept 9th. Please read more in the attached and advocate now!

Based on frequent request, Nimitt is excited to announce the first Nimitt Academy educational event – a webinar for Cell Therapy Program Administrators, focused on key aspects of CAR-T and SCT reimbursement. Please see the below link for registration and more information. https://lnkd.in/gSshpGtr

Stakeholders are needed to submit comments to CMS on the importance of providing hospitals with OPPS payment for outpatient CAR-T cell collection and cell processing services starting January 1, 2025. Read more in the attached and advocate now!

Calling all Providers: complete this brief survey to help the Nimitt team design the best Masterclass that reflects your most pressing education needs with respect to coverage, coding, billing, contracting, and reimbursement for cell and gene therapies.

Cell and Gene Therapy (CGT) program administrators, Nimitt Consulting has something very exciting in the works for hospitals – we'd love to hear what YOU think! Provide your feedback here: https://lnkd.in/gFGMKtY4 Follow our LinkedIn posts to stay in the know! @nimitt  #nimittacademy

With the majority of Medicare beneficiaries now enrolled in Medicare Advantage plans, we need access to MA data in the same way that stakeholders access Medicare fee-for-service data. This will enable analyses to occur, which is crucial since MA claims are not used in Medicare rate-setting and the impact of this unknown!   We at Nimitt Consulting see this as a major opportunity for improved policy-making – please read to understand this issue and submit comments to CMS before May 29. **Edit: Use the following link to submit comments to CMS: https://lnkd.in/dE8YUi4x

Nimitt Consulting's mission is to be a change agent and ensure that providers can care for their patients in the best way possible. One step forward is CMMI’s Cell and Gene Therapy Access Model, which is aimed at improving Medicaid beneficiaries’ access to transformative gene therapies for Sickle Cell Disease.   However, unless the Model addresses provider enrollment requirements for out-of-state Medicaid programs, insurmountable barriers will still hamper Medicaid beneficiaries' access to these therapies when needed outside of their home state. With a start date set in 2025, we urge CMMI to pilot a solution to address this problem as part of the Model.  Please join us by reading this piece, sharing it with your colleagues, and advocating for a change. As always, we welcome your comments and stay tuned for more on this topic!  #medicaid #patientaccess #cellandgenetherapies #cmmi